ClinicalTrials.gg

Program

abelacimab

Also written as “Abelacimab”, “MAA868” and “MAA868 Cohort 1”.

In Novartis's pipeline, FXI/FXIa inhibitor. Its studies are mostly in Atrial Fibrillation · Venous Thromboembolism, led by 2 companies.

Furthest: phase 3, since Nov 22, 20218 company-led studies, 3 open or runningNext primary completion: Dec 30, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Anthos Therapeutics52 open or runningphase 3since Nov 22, 2021Dec 23, 2019Dec 30, 2027phase 3 · NCT05712200
Novartis31 open or runningphase 3since Jul 28, 2026Jan 3, 2018Dec 30, 2030phase 3 · NCT07739888
  • Named in Novartis’s own pipeline as MAA868 (abelacimab), phase 3, as of Nov 16, 2026 (source).

Also a collaborator on its studies: covance.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 3, 2018First studies: 2 phase 2 studiesNew to NovartisNovartis · NCT03393481, NCT03398434
  2. Dec 23, 2019Anthos Therapeutics's first study: phase 2 study in Atrial FibrillationNew to Anthos TherapeuticsAnthos Therapeutics · NCT04213807 · 28 enrolled · United States
  3. Feb 11, 2021Phase 2 study in Atrial FibrillationAnthos Therapeutics · NCT04755283 · 1,287 enrolled · United States, Canada, Czechia and more
  4. Nov 22, 20212 phase 3 studies in Venous ThromboembolismAnthos Therapeutics · NCT05171075, NCT05171049
  5. Jan 12, 2023Phase 3 study in Atrial FibrillationAnthos Therapeutics · NCT05712200 · 2,500 planned · United States, Argentina, Brazil and more
  6. Jul 28, 2026Phase 3 study in Atrial FibrillationPhase 3 reachedNovartis · NCT07739888 · 2,500 planned

Ahead

  1. Dec 30, 2027Primary completion: phase 3 study in Atrial FibrillationAnthos Therapeutics · NCT05712200
  2. Dec 30, 2030Primary completion: phase 3 study in Atrial FibrillationNovartis · NCT07739888

TargetBeta

“FXI/FXIa inhibitor”the company's pipeline, read by Claude · source
“Coagulation factor XI inhibitor”ChEMBL 37, by rule

Other programs on F11

ProgramCompanyFurthest phaseStudies
milvexianBristol-Myers Squibbphase 325
SHR-2004Jiangsu HengRui Medicinephase 35

Studies

All 8 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07739888Atrial Fibrillation3Not yet recruitingNovartisDec 30, 20302,500
NCT05712200Atrial Fibrillation · United States, Argentina, Brazil and more3RecruitingAnthos TherapeuticsDec 30, 20272,500
NCT05171075Venous Thromboembolism · United States, Australia, Austria and more3TerminatedAnthos TherapeuticsApr 10, 2026417
NCT05171049Venous Thromboembolism · United States, Australia, Austria and more3TerminatedAnthos TherapeuticsFeb 4, 20261,150
NCT04755283Atrial Fibrillation · United States, Canada, Czechia and more2Active, not recruitingAnthos TherapeuticsFeb 15, 20241,287
NCT04213807Atrial Fibrillation · United States2CompletedAnthos TherapeuticsDec 29, 202028
NCT03398434Atrial Fibrillation2WithdrawnNovartisNov 28, 20190
NCT03393481Venous Thromboembolism2WithdrawnNovartisJan 8, 20200

How it is read

Names in the registry

  • “Abelacimab”, 5 entries
  • “MAA868”, 2 entries
  • “MAA868 Cohort 1”, 1 entry
  • “MAA868 Cohort 2”, 1 entry
  • “MAA868 Cohort 3”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.